HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

45.600

+1.8004.11%

Volume:3.84M

Turnover:173.09M

Market Cap:302.65B

PE:33.06

High:45.660

Open:43.780

Low:43.760

Close:43.800

52wk High:94.869

52wk Low:43.020

Shares:6.64B

HK Float Shares:258.00M

Volume Ratio:1.15

T/O Rate:1.49%

Dividend:0.23

Dividend Rate:0.51%

EPS(LYR):1.379

ROE:12.46%

ROA:7.02%

PB:4.02

PE(LYR):33.06

PS:8.27

Loading ...

Overview Company News Filings

Hong Kong Stock Market Update: Hengrui Pharma Surges Nearly 4% in Late Trading Following Dual Clinical Trial Approvals

China's Jiangsu Hengrui Climbs on Clinical Trial Approval for Stroke Drug

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Recaticimab Injection

MT Newswires Live

Movement Alert｜HENGRUI PHARMA Rises 3.01% in Regular Trading, Dense Pipeline Milestones Boost Market Sentiment

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.17% on Sept 10 from 6.56% - HKEX

THOMSON REUTERS

Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials

Chinese Drug Regulator Accepts Hengrui Pharmaceuticals Unit's Marketing Application for SHR-2004 Injection

MT Newswires Live

Big Pharma is Pouring Billions into China's Biotechs

Movement Alert｜HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

MT Newswires Live

Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets

MT Newswires Live

Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets

THOMSON REUTERS

Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets

Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress

China Accepts Hengrui Pharma Unit's Marketing Application for Diabetes Drug

MT Newswires Live

AH Share Premium Rankings as of September 9 Trading Close

Hengrui Pharma Sets 24 Sep 2026 EGM to Vote on Dual Employee Share Schemes and 10% H-Share Buyback Mandate

Bulletin Express

Hengrui Pharma Seeks Approval for 2026 Dual-Class Incentive Plans and 10% H-Share Buy-Back Authority

Bulletin Express

Hengrui Pharma Wins China Clinical Trial Nod For Two Weight Management Products

MT Newswires Live

Hengrui Pharmaceuticals Gets China Nod to Trial Two Tumor Drugs

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/01276/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":45.6,"timestamp":1789546126004,"preClose":43.8,"halted":0,"volume":3837300,"delay":0,"changeRate":0.041095890410959006,"floatShares":258000000,"shares":6637000000,"eps":1.3791504549733289,"marketStatus":"Not Yet Opened","change":1.8,"latestTime":"09-16 16:08:46","open":43.78,"high":45.66,"low":43.76,"amount":173093690,"amplitude":0.043379,"askPrice":45.6,"askSize":2800,"bidPrice":45.5,"bidSize":6800,"shortable":3,"etf":0,"ttmEps":1.3600877906338245,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":43.8,"dividendRate":0.005117,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":1.153645442042134,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":43.52,"timestamp":1789542000000,"preClose":43.13,"halted":0,"volume":41619500,"delay":0,"premium":"-10.35"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"7.02%","roe":"12.46%","lyrEps":1.37915,"volumeRatio":1.153645442042134,"shares":6637000000,"dividePrice":0.233754,"high":45.66,"amplitude":0.043379,"preClose":43.8,"low":43.76,"week52Low":43.02,"pbRate":"4.02","psRate":"8.27","week52High":94.869,"institutionHeld":0,"latestPrice":45.6,"committee":0.416667,"eps":1.3791504549733289,"divideRate":0.005126,"volume":3837300,"delay":0,"ttmEps":1.3600877906338245,"open":43.78,"prevYearClose":71.002,"prevWeekClose":43.76,"prevMonthClose":46.06,"prevQuarterClose":57.85,"fiveDayClose":45.94,"twentyDayClose":54.95,"sixtyDayClose":56.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787103000000,"name":null,"time":"","dateTimestamp":1787068800000,"actualEps":null},{"date":"2026-04-29","symbol":"01276","amount":0.22828,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-30","defaultRemindTime":1777426200000,"name":"恒瑞医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-04-30","currency":"HKD","dateTimestamp":1777392000000,"payDate":"2026-05-27"},{"date":"2026-04-22","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776821400000,"name":null,"time":"","dateTimestamp":1776787200000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[{"executeDate":"2026-04-29","recordDate":"2026-04-30","paymentDate":"2026-05-27","value":0.22828,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-09-15","current":33.505579,"percent":0.006154,"low":36.382401,"twenty":43.838117,"median":51.680663,"eighty":56.988635,"high":65.582363,"avg":51.116294,"sd":7.452416,"marketCap":331810565089.89},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-10","current":49.055344,"twenty":50.995993,"median":54.897923,"eighty":60.186394,"marketCap":433687668394.36},{"date":"2026-04-17","current":48.417764,"twenty":50.589497,"median":54.65026,"eighty":60.143018,"marketCap":428230701835.75},{"date":"2026-04-24","current":45.835792,"twenty":50.342877,"median":54.475147,"eighty":60.015062,"marketCap":426879682872.04},{"date":"2026-04-30","current":44.026312,"twenty":50.285416,"median":54.355253,"eighty":59.903394,"marketCap":410132737659.64},{"date":"2026-05-08","current":43.161515,"twenty":50.207478,"median":54.262074,"eighty":59.804539,"marketCap":403472171949.3},{"date":"2026-05-15","current":44.128138,"twenty":49.985706,"median":54.115335,"eighty":59.70386,"marketCap":413593092820.6},{"date":"2026-05-22","current":41.244553,"twenty":49.583265,"median":53.983854,"eighty":59.631568,"marketCap":385683097978.4},{"date":"2026-05-29","current":40.98659,"twenty":49.34142,"median":53.840414,"eighty":59.564678,"marketCap":384603594259.51},{"date":"2026-06-05","current":38.394132,"twenty":49.063316,"median":53.633194,"eighty":59.459458,"marketCap":360799766229.36},{"date":"2026-06-12","current":39.515262,"twenty":48.81081,"median":53.517715,"eighty":59.36625,"marketCap":371084155232.86},{"date":"2026-06-18","current":39.444808,"twenty":48.417764,"median":53.467699,"eighty":59.301536,"marketCap":371311256576.18},{"date":"2026-06-26","current":39.60241,"twenty":47.951326,"median":53.090114,"eighty":59.187086,"marketCap":370974287810.31},{"date":"2026-07-03","current":44.319925,"twenty":47.638943,"median":53.015805,"eighty":59.069259,"marketCap":415476044901.86},{"date":"2026-07-10","current":45.319748,"twenty":47.348429,"median":52.993744,"eighty":59.024871,"marketCap":424327469311.14},{"date":"2026-07-17","current":43.189222,"twenty":46.151454,"median":52.805265,"eighty":58.96135,"marketCap":405818502739.33},{"date":"2026-07-24","current":43.433009,"twenty":45.632553,"median":52.604835,"eighty":58.912251,"marketCap":408200902707.63},{"date":"2026-07-31","current":43.935338,"twenty":45.29749,"median":52.543618,"eighty":58.877468,"marketCap":413706414238.87},{"date":"2026-08-07","current":44.394532,"twenty":45.008473,"median":52.339287,"eighty":58.813302,"marketCap":418841988303.56},{"date":"2026-08-14","current":42.6704,"twenty":44.628794,"median":52.189578,"eighty":58.452058,"marketCap":403085247281.44},{"date":"2026-08-21","current":40.686911,"twenty":44.408765,"median":52.120101,"eighty":57.75211,"marketCap":366558497066.13},{"date":"2026-08-28","current":40.334802,"twenty":44.24321,"median":51.814807,"eighty":57.336246,"marketCap":363468645736.13},{"date":"2026-09-04","current":39.220129,"twenty":44.050964,"median":51.771686,"eighty":57.152374,"marketCap":353565883607.49},{"date":"2026-09-11","current":36.382401,"twenty":43.912617,"median":51.717719,"eighty":57.022157,"marketCap":328426636361.34},{"date":"2026-09-15","current":36.763247,"twenty":43.838117,"median":51.680663,"eighty":56.988635,"marketCap":331810565089.89}],"updateTime":1789567098337},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1177370867","title":"Hong Kong Stock Market Update: Hengrui Pharma Surges Nearly 4% in Late Trading Following Dual Clinical Trial Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=1177370867","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177370867?lang=en_us&edition=fundamental","pubTime":"2026-09-16 15:52","pubTimestamp":1789545137,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) saw its shares climb nearly 4% during the final stretch of Thursday's trading session, buoyed by regulatory approvals for two distinct clinical programs targeting separate...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU2097828557.USD","LU1997245177.USD","BK0028","BK0060","LU1580142542.USD","LU2328871848.SGD","LU1969619763.USD","LU2580892789.USD","LU0359202008.SGD","IBBJ","LU2289578879.USD","LU1997244956.HKD","BK4588","LU2097828631.EUR","LU2097828805.USD","600276","LU2097828714.EUR","BK0012","BK0239","KCAI","BK1191","LU1146622755.USD","LU1820825898.SGD","LU2543165471.USD","LU1655091616.SGD","BK0196","LU2580892862.HKD","BK4585","VXUS","LU1781817850.SGD","LU2495084118.USD","LU1328615791.USD","LU1997245094.SGD","LU0359201612.USD","LU1023057109.AUD","LU1064130708.USD","LU2488822045.USD","LU1064131003.USD","LU2097828474.EUR","BK0188","LU2148510915.USD","BMED","LU0405327494.USD","BK0183","MDTX","IBBQ","01276","LU0359201885.HKD","LU1255011170.USD","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667603734","title":"China's Jiangsu Hengrui Climbs on Clinical Trial Approval for Stroke Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667603734","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667603734?lang=en_us&edition=fundamental","pubTime":"2026-09-16 15:38","pubTimestamp":1789544325,"startTime":"0","endTime":"0","summary":"BUZZ-China's Jiangsu Hengrui climbs on clinical trial approval for stroke drug** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals1276.HKclimb 3.5% to HK$45.34, on course for the biggest one-day pct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL1N45806E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU0359201612.USD","LU1781817850.SGD","LU1997244956.HKD","LU1655091616.SGD","LU0405327494.USD","BK0239","LU2328871848.SGD","LU1023057109.AUD","LU1580142542.USD","LU1997245094.SGD","LU0359202008.SGD","LU2495084118.USD","LU2097828557.USD","LU2148510915.USD","BK0183","BK0188","LU2097828631.EUR","01276","LU2580892789.USD","LU2097828805.USD","LU0359201885.HKD","LU2488822045.USD","LU1820825898.SGD","BK0060","BK0012","LU1969619763.USD","LU2289578879.USD","LU1328615791.USD","LU1064131003.USD","BK0028","LU1146622755.USD","BK1191","BK0196","LU2580892862.HKD","600276","LU1064130708.USD","LU2097828714.EUR","LU0405327148.USD","LU1997245177.USD","LU2543165471.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667679529","title":"Hengrui Pharmaceuticals' Unit Gets Nod to Trial Recaticimab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667679529","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667679529?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:29","pubTimestamp":1789525750,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit, Guangdong Hengrui Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trial of recaticimab injection, according to a Shanghai bourse filing on Wednesday.The drug is used to treat adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrent stroke.The pharmaceutical company invested 422.2 million yuan into the research and development of the drug.The company's Hong Kong shares rose 2% during the morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1146622755.USD","LU2097828631.EUR","LU2328871848.SGD","BK0196","LU1064130708.USD","BK0028","LU1997244956.HKD","LU1997245094.SGD","LU2148510915.USD","BK0239","LU2097828805.USD","LU2495084118.USD","LU1023057109.AUD","LU1820825898.SGD","LU2580892862.HKD","LU2097828557.USD","01276","LU1328615791.USD","LU1781817850.SGD","LU1580142542.USD","LU2488822045.USD","LU2580892789.USD","LU2289578879.USD","LU0359202008.SGD","BK0012","LU0359201885.HKD","LU1969619763.USD","600276","LU1255011170.USD","LU0405327148.USD","BK0060","BK0188","BK1191","BK0183","LU2543165471.USD","LU2097828714.EUR","LU1997245177.USD","LU0359201612.USD","LU0405327494.USD","LU2097828474.EUR","LU1064131003.USD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111961748","title":"Movement Alert｜HENGRUI PHARMA Rises 3.01% in Regular Trading, Dense Pipeline Milestones Boost Market Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1111961748","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111961748?lang=en_us&edition=fundamental","pubTime":"2026-09-16 09:51","pubTimestamp":1789523514,"startTime":"0","endTime":"0","summary":"On September 16, HENGRUI PHARMA rose 3.01% in regular trading, trading at HKD 45.0/share, with turnover of HKD 39.16 million. The rally was driven by a rapid succession of pipeline catalysts spanning...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Hengrui Pharma Rises on Multiple Pipeline Milestones","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648643","title":"BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.17% on Sept 10 from 6.56% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648643?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:27","pubTimestamp":1789464478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4570BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0405327494.USD","LU1328615791.USD","LU2289578879.USD","BK0012","BK0060","LU2580892862.HKD","LU2580892789.USD","LU0359201885.HKD","LU0359201612.USD","LU2097828714.EUR","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","BK0188","LU1064130708.USD","LU1146622755.USD","LU1580142542.USD","LU2543165471.USD","BK0028","LU1969619763.USD","600276","01276","BK0196","LU1655091616.SGD","LU0359202008.SGD","LU2097828631.EUR","BK0183","LU1997245177.USD","LU2097828557.USD","LU2488822045.USD","LU1023057109.AUD","LU2097828474.EUR","LU2495084118.USD","BK0239","BK1191","LU1997245094.SGD","LU0405327148.USD","LU1820825898.SGD","LU2328871848.SGD","LU1997244956.HKD","LU2097828805.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151952155","title":"Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1151952155","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151952155?lang=en_us&edition=fundamental","pubTime":"2026-09-15 16:42","pubTimestamp":1789461741,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327494.USD","MDTX","LU1328615791.USD","LU2289578879.USD","BK0012","BMED","BK0060","LU2580892862.HKD","LU2580892789.USD","IBBQ","LU0359201885.HKD","LU0359201612.USD","LU2097828714.EUR","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","BK0188","LU1064130708.USD","LU1146622755.USD","LU1580142542.USD","LU2543165471.USD","BK0028","LU1969619763.USD","600276","01276","BK0196","LU1655091616.SGD","LU0359202008.SGD","LU2097828631.EUR","PSYK","BK0183","LU1997245177.USD","LU2097828557.USD","LU2488822045.USD","LU1023057109.AUD","LU2097828474.EUR","LU2495084118.USD","BK0239","IBBJ","BK1191","LU1997245094.SGD","LU0405327148.USD","LU1820825898.SGD","LU2328871848.SGD","LU1997244956.HKD","LU2097828805.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690619","title":"Chinese Drug Regulator Accepts Hengrui Pharmaceuticals Unit's Marketing Application for SHR-2004 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690619","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690619?lang=en_us&edition=fundamental","pubTime":"2026-09-15 10:06","pubTimestamp":1789437982,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the drug marketing authorization application of Jiangsu Hengrui Pharmaceuticals'  unit, Beijing Shengdi Pharmaceutical, for SHR-2004 injection, according to a Tuesday disclosure in a Shanghai bourse filing.The drug is used to prevent venous thromboembolism in adult patients undergoing elective knee replacement surgery.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359202008.SGD","01276","LU1023057109.AUD","LU0359201612.USD","LU2543165471.USD","BK1191","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656927","title":"Big Pharma is Pouring Billions into China's Biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656927","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656927?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:59","pubTimestamp":1789372740,"startTime":"0","endTime":"0","summary":"China's biotech industry has become as much a challenger to America's technological leadership as China's artificial intelligence upstarts.Big Pharma firms have cut license deals worth tens of billion","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","IE00BJT1NW94.SGD","LU0130517989.USD","LU0516423091.SGD","BK4532","LU0456827905.SGD","LU2360032135.SGD","LU2289578879.USD","SG9999002562.SGD","IE00BJJMRZ35.SGD","IYH","LU0306806265.USD","LU0058720904.USD","LU0124676726.USD","LU1989772923.USD","LU2125154935.USD","LU0540923850.HKD","LU1008478684.HKD","LU1066051225.USD","BK0196","IHE","LU1868836914.USD","LU0516422440.USD","LU2089984988.USD","LU2361044949.HKD","LU0588546209.SGD","IE00BFXG1179.USD","HK0000165453.HKD","IE0009355771.USD","GSK.UK","LU0868494617.USD","LU0859254822.USD","LU1997244956.HKD","BK1161","LU0051755006.USD","LU1162221912.USD","LU0061475181.USD","IE00B19Z3B42.SGD","IE00B031HY20.USD","LU0128525929.USD","LU0289739343.SGD","LU1997245094.SGD","BK4007","LU1430594728.SGD","LU1037948897.HKD","BK1574","LU0359202008.SGD","LU1934455194.USD","LU1032466523.USD","LU0320764599.SGD","IE00BLSP4239.USD","LU0140636845.USD","IE00B5MMRT66.SGD","LU0029864427.USD","IE00BFTCPJ56.SGD","BK1610","09926","LU2097828805.USD","BK4588","LU0310800379.SGD","IE00BZ08YT58.USD","IE0002141913.USD","LU0477156953.USD","LU1868836757.USD","LU0234572021.USD","PAWZ","LU1585245621.USD","LU1267930573.SGD","LU0856984785.SGD","LU1951186391.HKD","LU1989771016.USD","LU0057025933.USD","BK4526","LU2462157665.USD","LU0348783233.USD","LU2596442595.SGD","LU1829250122.USD","LU0348825331.USD","LU0106261372.USD","LU0942090050.USD","LU0320765489.SGD","BK0028","LU1093756168.USD","LU1116320901.HKD","LU1983299246.USD","LU2495084118.USD","LU1813983027.USD","LU0432979614.USD","SG9999001440.SGD","LU0265550946.USD","LU2023250504.SGD","IE00B543WZ88.USD","LU0267386448.USD","GSK","LU2237443895.HKD","LU2361044865.SGD","LU2242646821.SGD","LU1894683264.USD","LU1718418525.SGD","LU2580892789.USD","SG9999015341.SGD","LU0882574055.USD","LU1328615791.USD","LU0417516738.SGD","LU1580142542.USD","01801","IE0008368742.USD","LU1066051811.HKD","LU0516423174.USD","LU0708994859.HKD","LU0122379950.USD","IE000M9KFDE8.USD","09688","LU0320765646.SGD","LU0516422952.EUR","LU1057294990.SGD","LU1226287529.USD","LU1929549753.HKD","LU1064131003.USD","LU0417516571.SGD","LU2399975544.HKD","LU0130102774.USD","LU0306807586.USD","LU1261432733.SGD","LU2580892862.HKD","PPH","LU1066053197.SGD","SG9999002224.SGD","LU0359201612.USD","LU2417539215.USD","LU1146622755.USD","LU1069347547.HKD","IE00BZ08YS42.EUR","IE0008369823.USD","LU0244354667.USD","LU1807302812.USD","BK1521","BMY","BK4139","LU0348766576.USD","LU1831875114.USD","SG9999011175.SGD","BK1589","LU0861579265.USD","XLV","LU1226287792.SGD","LU2097828557.USD","LU2324357040.USD","LU1571399168.USD","LU0985481810.HKD","SG9999004220.SGD","01276","LU0289961442.SGD","LU0572944931.SGD","BK4585","LU0819121731.USD","LU0472753341.HKD","LU1960683339.HKD","SGXZ57979304.SGD","LU0181495838.USD","LU0979878070.USD","LU2476274720.SGD","LU1093756325.SGD","LU0965508806.USD","LU0980610538.SGD","LU0823426308.USD","LU0607220059.USD","IE00BPRC5H50.USD","LU0314109678.HKD","LU0823426480.USD","GDOC","LU0307460666.USD","LU0456855351.SGD","LU1074936037.SGD","LU0096364046.USD","LU1961090484.USD","LU2476274308.USD","LU0455707207.USD","LU0170899867.USD","LU1655091616.SGD","LU1941712264.USD","LU2433249047.HKD","LU2237443622.USD","BMED","SG9999013999.USD","LU1066051498.USD","BK4592","JDOC","BK0188","LU0405327148.USD","LU0634319403.HKD","LU1974910355.USD","LU2023250843.SGD","LU2461242641.AUD","LU0203345920.USD","LU0225771236.USD","BK4559","LU2242652126.USD","LU1934455863.HKD","LU0965509010.AUD","LU1236620750.USD","BK4599","01177","LU2491050071.SGD","LU0225284248.USD","BK0183","LU0315179316.USD","BK0239","LU1997245177.USD","LU0067412154.USD","LU1868837300.USD","LU0985320562.USD","LU0266013472.USD","LU1894683348.USD","LU0006306889.USD","BK1576","LU0327786744.USD","LU2778985437.USD","LU2237443382.USD","LU1035773651.USD","LU2237443465.HKD","LU2357627491.SGD","BK4581","LU2328871848.SGD","BK4516","WXXWY","LU0208291251.USD","SG9999003800.SGD","LU0128526141.USD","LU0069063385.USD","LU0348827113.USD","LU0880133367.SGD","LU1226287875.USD","LU0043850808.USD","LU0289739699.SGD","LU0072913022.USD","LU1236620834.HKD","LU2097828714.EUR","BK1515","SBHMY","LU1688375341.USD","LU2491050154.USD","LU0114720955.EUR","RXL","LU1226288253.USD","LU0321505868.SGD","LU1188198961.HKD","LU2125909593.SGD","BK4568","IE00B2B36J28.USD","IE00B0JY6N72.USD","LU0648001328.SGD","LU1720050803.USD","LU2242644610.SGD","OZEM","BK0060","LU0889565916.HKD","LU1941712348.USD","SG9999014542.SGD","02269","LU1670710661.SGD","LU2237443978.SGD","IXJ","LU1794554557.SGD","LU0326950275.SGD","LU0561508036.HKD","IE00B3T34201.USD","LU1670711040.USD","BK4550","01093","LU1917777945.USD","600276","LU3063872942.SGD","IE00BLSP4452.SGD","BK0012","AZN","GSKH","AZNH","LU2456880835.USD","LU0708995583.HKD","LU0868494708.USD","LU1255011170.USD","LU1993786604.SGD","LU0052750758.USD","LU1201861249.SGD","BK1583","LU1699723380.USD","LU2236285917.USD","LU2039709279.SGD","ZLAB","LU1023059063.AUD","LU0823416689.USD","LU0965509283.SGD","LU0348735423.USD","KURE","IE00B19Z3581.USD","IE00BZ08YR35.GBP","FHLC","LU0039217434.USD","LU1868837136.USD","LU1328277881.USD","LU0516422366.SGD","LU0265550359.USD","IE00BBT3K403.USD","LU0237698245.USD","SG9999015358.SGD","BK4548","IE0002270589.USD","LU0405327494.USD","LU2097828474.EUR","BK4533","SG9999001176.USD","LU0238689110.USD","TRUH","LU1820825898.SGD","FTXH","BK1191","IE00BN8TJ469.HKD","LU0417516902.SGD","HRTS","LU1934455277.USD","LU1226288170.HKD","LU0070302665.USD","LU1242518931.SGD","SG9999014567.USD","LU2237443549.SGD","LU0149534421.HKD","LU0463099449.HKD","LU0211331839.USD","LU1670710588.SGD","LU1781817850.SGD","LU0501845795.SGD","LU2106854487.HKD","LU0109394709.USD","LU2468319806.SGD","LU2148510915.USD","LU2361045086.USD","LU1152091168.USD","LU1064130708.USD","BK1141","LU1923622614.USD","SG9999014575.USD","VHT","LU0348767384.USD","LU1152091754.HKD","LU2488822045.USD","LU1883839398.USD","MRK","LU0348784397.USD","IE00BSNM7G36.USD","LU0203347892.USD","LU1868836591.USD","LU1323610961.USD","LU0456846285.SGD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","LU1670711123.USD","LU1291159041.SGD","LU2125154778.USD","LU2491049909.HKD","BK4531","LU0502904849.HKD","LU1989772840.SGD","BK4534","LU0321505439.SGD","LU0029874061.USD","LU2112291526.USD","LU1880383366.USD","LU0320765992.SGD","LU2125909247.SGD","LU2097828631.EUR","LU1061106388.HKD","SG9999001176.SGD","LU2133065610.SGD","LU0098860793.USD","LU1116320737.USD","SG9999014559.SGD","SG9999002232.USD","LU0511384066.AUD","LU1969619763.USD","SMMT","LU0689626769.HKD","LU1037948541.HKD","LU1242518857.USD","LU0965509101.SGD","SG9999002463.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152020231","title":"Movement Alert｜HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=1152020231","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152020231?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:27","pubTimestamp":1789367244,"startTime":"0","endTime":"0","summary":"On September 14, HENGRUI PHARMA rose 3.2% in regular trading, trading at HK$45.16/share, with turnover of approximately HK$86.20 million. The gain was driven by a recent announcement that the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"HENGRUI PHARMA Gains as HER3 ADC Gets Breakthrough Therapy Tag","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667263452","title":"Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=2667263452","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667263452?lang=en_us&edition=fundamental","pubTime":"2026-09-14 10:45","pubTimestamp":1789353956,"startTime":"0","endTime":"0","summary":"China's drug regulator included Jiangsu Hengrui Pharmaceuticals  subsidiary Suzhou Shengdia Biopharmaceutical's ruzaltatug rezetecan drug for non-small cell lung cancer in its breakthrough therapy designation list, according to a Saturday filing with the Shanghai bourse.The drug is indicated for combination with bevacizumab to treat advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK1191","LU1064131003.USD","LU2328871848.SGD","LU2580892862.HKD","LU1580142542.USD","LU2289578879.USD","BK0183","LU0405327148.USD","LU2097828557.USD","LU1023057109.AUD","LU0405327494.USD","LU1997245094.SGD","LU2148510915.USD","LU2580892789.USD","LU2543165471.USD","BK0012","LU2488822045.USD","LU2097828474.EUR","01276","LU2495084118.USD","LU1255011170.USD","LU1820825898.SGD","LU1655091616.SGD","LU1997245177.USD","LU2097828714.EUR","LU1064130708.USD","BK0188","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","LU1146622755.USD","LU0359202008.SGD","LU1969619763.USD","LU1328615791.USD","LU2097828631.EUR","BK0028","600276","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666737560","title":"Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2666737560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666737560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:23","pubTimestamp":1789039426,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval for two new indications of its Hetrombopag Olamine Tablets from China's  National Medical Products Administration.The first indication is for the treatment of adult patients with thrombocytopenia caused by chemotherapy-based anti-tumor therapy for solid tumors, according to a Thursday bourse filing.The other indication is for pediatric patients over six years of age with chronic primary immune thrombocytopenia.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201612.USD","BK1191","01276","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666679065","title":"Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2666679065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666679065?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:46","pubTimestamp":1789037160,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131003.USD","LU2543165471.USD","LU0359202008.SGD","LU1255011170.USD","LU2097828805.USD","LU2328871848.SGD","LU2148510915.USD","600276","LU1969619763.USD","BK0060","LU2580892862.HKD","LU2580892789.USD","LU1820825898.SGD","LU1023057109.AUD","LU2097828631.EUR","LU2289578879.USD","LU2488822045.USD","BK1191","LU0405327494.USD","LU1997245094.SGD","LU0359201885.HKD","LU1655091616.SGD","LU1997244956.HKD","LU0359201612.USD","LU2097828714.EUR","BK0196","LU1064130708.USD","BK0183","LU2097828474.EUR","01276","BK0188","LU2495084118.USD","BK0028","LU0405327148.USD","LU1328615791.USD","LU1580142542.USD","LU1781817850.SGD","LU1146622755.USD","LU2097828557.USD","LU1997245177.USD","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115847199","title":"Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847199","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115847199?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:54","pubTimestamp":1789034083,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it recently received notification from China's National Medical Products Administration, granting approval for two additional...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU2097828631.EUR","BK0012","BK0196","BK0028","LU1997244956.HKD","LU1146622755.USD","BK1191","LU2097828557.USD","LU1997245094.SGD","LU1997245177.USD","LU0359202008.SGD","LU2580892862.HKD","LU2097828474.EUR","LU2148510915.USD","LU2495084118.USD","LU2289578879.USD","LU1781817850.SGD","LU1255011170.USD","LU1969619763.USD","LU2488822045.USD","LU0405327494.USD","LU1064131003.USD","LU1328615791.USD","LU1064130708.USD","LU2328871848.SGD","LU2580892789.USD","01276","BK0183","BK0239","LU2097828805.USD","LU1580142542.USD","LU1023057109.AUD","BK0060","600276","LU0405327148.USD","LU1820825898.SGD","LU2097828714.EUR","BK0188","LU2543165471.USD","LU0359201885.HKD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143529951","title":"Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1143529951","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143529951?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:48","pubTimestamp":1789008515,"startTime":"0","endTime":"0","summary":"On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.The decline came amid a broad selloff across the pharmaceuticals sector,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Hengrui Falls Amid Pharma Selloff Despite NMPA Drug Filing","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551019","title":"China Accepts Hengrui Pharma Unit's Marketing Application for Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551019","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551019?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:45","pubTimestamp":1789008337,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the marketing application of Jiangsu Hengrui Pharmaceuticals'  unit, Fujian Shengdi Pharmaceutical, for repaglinide, according to a Thursday disclosure on the Shanghai bourse.The drug is indicated for glycemic control in adult patients with type 2 diabetes mellitus.The pharmaceutical company's shares fell 3% during the morning trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU2543165471.USD","BK1191","01276","LU0359202008.SGD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194600066","title":"AH Share Premium Rankings as of September 9 Trading Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1194600066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194600066?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:24","pubTimestamp":1788942275,"startTime":"0","endTime":"0","summary":"As of the market close on September 9, three companies lead the A-H share premium rankings for the session. NE ELECTRIC (00042) tops the list with a premium of 1121.72%, followed by ZHEJIANG SHIBAO...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1282648689.USD","LU0449509016.USD","LU0106959298.USD","BK1163","03308","LU1988902786.USD","BK1149","LU0543330483.HKD","LU0164939612.USD","LU0572944931.SGD","LU0181495838.USD","BK1148","LU2097828474.EUR","LU0164865239.USD","LU0254981946.USD","LU0307460666.USD","LU2097828805.USD","00317","LU1244550221.USD","SG9999014674.SGD","06869","BK1147","BK1515","03200","BK1190","LU0328353924.USD","LU1244550494.USD","01033","02827","BK1546","LU0329678170.USD","LU1046422090.SGD","LU2097828557.USD","BK1198","LU2264538146.SGD","HK0001040143.USD","BK1544","LU1960683339.HKD","LU1152091168.USD","00553","00991","LU1504937902.USD","02338","IE00B0169L03.USD","LU2399975544.HKD","HK0000306685.HKD","159982","LU0509642566.USD","LU0620787316.HKD","LU1655091616.SGD","03328","03130","LU0029875118.USD","LU1961090484.USD","LU0269904917.USD","HK0001040168.HKD","LU2226246903.HKD","LU0561508036.HKD","LU1808992512.USD","BK1161","BK1514","LU1719994722.HKD","LU2177674079.SGD","LU0082770016.USD","02068","LU0417516902.SGD","BK1506","LU0463099449.HKD","LU0173614495.USD","LU1244550577.SGD","LU0828237510.HKD","LU1831875114.USD","LU1255011170.USD","BK1122","LU1769817096.USD","LU0431992006.USD","LU1152091754.HKD","LU0266512473.USD","LU0348766576.USD","06066","01276","BK1552","EWH","BK1141","LU0359201885.HKD","LU0918141887.USD","BK1530","LU0868486357.SGD","BK1560","BK1191","LU2008162690.USD","LU0348735423.USD","LU0061477393.USD","LU0588546209.SGD","BK1583","HK0000320223.HKD","BK1214","LU0370786039.SGD","LU0871576103.HKD","03750","IE0034224299.USD","LU1064131342.USD","BK1237","06821","LU0359202008.SGD","BK1183","LU2045819591.USD","LU2242644610.SGD","LU0067412154.USD","01108","83188","LU0359201612.USD","LU0456854461.SGD","LU0049853897.USD","BK1110","02475","LU0737861699.HKD","BK1140","BK1537","LU1242518931.SGD","LU1251922891.USD","LU0211977185.USD","LU0228659784.USD","LU0345780281.USD","BK1125","82846","01057","LU0039217434.USD","LU0348767384.USD","LU0531971595.HKD","LU0149721374.USD","02359","LU0326950275.SGD","LU0348825331.USD","LU2097828631.EUR","00895","LU0314109678.HKD","BK1533","IE00BZ08YS42.EUR","LU0797268264.HKD","07233","BK1171","LU1993786604.SGD","LU0345780521.USD","LU0128522157.USD","LU0348816934.USD","LU0106252389.USD","LU0979878070.USD","LU0828237940.HKD","LU1206782309.USD","LU0828238088.HKD","BK1576","SG9999001093.SGD","BK1551","LU0607220059.USD","LU1303224171.USD","01812","LU0821914370.USD","LU0348827113.USD","01877","01349","LU0287142896.SGD","LU0052750758.USD","LU1105468828.SGD","00300","LU0320764755.SGD","LU3063872942.SGD","IE00BZ08YR35.GBP","BK1202","02218","06745","LU1720050803.USD","LU1794554557.SGD","BK1223","00042","LU0886674414.USD","LU1769817179.HKD","HK0000320264.USD","LU1023057109.AUD","LU2039709279.SGD","LU1807302812.USD","00187","BK1193","LU0165289439.USD","BK1523","BK1116","BK1554","BK1562","LU0096374516.USD","LU0417516738.SGD","LU0708995583.HKD","LU0082770016.SGD","LU0327786744.USD","LU1188198961.HKD","LU1770034418.SGD","LU0043850808.USD","LU0531970944.HKD","BK1105","09976","LU2097828714.EUR","LU1048596156.SGD","03188","LU1008478684.HKD","BK1594","LU1813983027.USD","LU1481107354.HKD","LU0149534421.HKD","BK1249","LU0140636845.USD","LU0634319403.HKD","SG9999011746.SGD","LU0164880469.USD","IE0032431581.USD","LU0320764599.SGD","LU0244354667.USD","LU0880133367.SGD","03986","BK1610","LU0737861772.HKD","BK1592","BK1170","LU2543165471.USD","LU0048580855.USD","LU1328277881.USD","02846","BK1564","LU0672654166.SGD","IE00BZ08YT58.USD","03678","LU0329678337.USD","02865","LU0540923850.HKD","LU0266512127.USD","LU2394011477.USD","LU0918141705.HKD","HK0000306701.USD","SG9999002463.SGD","SG9999004220.SGD","BK1522","83130","BK1231","SG9999006597.SGD","LU0348814723.USD","02899","BK1505","LU0214875030.USD","LU2125910500.SGD","LU1242518857.USD","LU1224709979.USD","SG9999001226.SGD","399300","LU0469268626.HKD","BK1144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180880506","title":"Hengrui Pharma Sets 24 Sep 2026 EGM to Vote on Dual Employee Share Schemes and 10% H-Share Buyback Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1180880506","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180880506?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868892,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) has issued the proxy form for its 2026 First Extraordinary Shareholders’ Meeting (EGM), scheduled for 2:30 p.m. on Thursday, 24 September...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136946420","title":"Hengrui Pharma Seeks Approval for 2026 Dual-Class Incentive Plans and 10% H-Share Buy-Back Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1136946420","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136946420?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:43","pubTimestamp":1788867786,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) has issued a circular convening its first extraordinary shareholders’ meeting for 24 September 2026 to vote on a suite of capital and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665234138","title":"Hengrui Pharma Wins China Clinical Trial Nod For Two Weight Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2665234138","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665234138?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:19","pubTimestamp":1788837571,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  subsidiaries received clinical trial approval from China's National Medical Products Administration for two weight management tablets, HRS-1597 and SHR-1179, according to separate Tuesday filings with the Shanghai bourse.Research and development investment for the HRS-1597 product so far reached 16.9 million yuan, while that for SHR-1179 is at 24.2 million yuanThe drug company's Hong Kong and Shanghai shares slipped 1% during Tuesday's morning session.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828557.USD","LU1655091616.SGD","LU1997245177.USD","LU1781817850.SGD","LU0405327494.USD","LU0359201885.HKD","BK0196","BK0239","LU0359202008.SGD","BK0188","LU2097828631.EUR","LU2488822045.USD","LU1820825898.SGD","LU2097828714.EUR","LU2495084118.USD","LU2289578879.USD","600276","BK0183","LU0359201612.USD","LU1064130708.USD","LU2580892862.HKD","BK0028","LU1997245094.SGD","LU1023057109.AUD","BK1191","BK0012","LU2097828474.EUR","LU1255011170.USD","LU1328615791.USD","LU1969619763.USD","LU1146622755.USD","LU1997244956.HKD","LU2097828805.USD","LU0405327148.USD","LU2328871848.SGD","LU2148510915.USD","LU2543165471.USD","01276","LU2580892789.USD","LU1064131003.USD","LU1580142542.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341844","title":"Hengrui Pharmaceuticals Gets China Nod to Trial Two Tumor Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341844","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341844?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:17","pubTimestamp":1788837431,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval from China's National Medical Products Administration for the clinical trials of HRS-6209 capsules and HRS-4508 tablets, according to a Shanghai bourse filing on Tuesday.HRS-6209 is a novel selective CDK4 inhibitor that is clinically intended for the treatment of advanced malignant solid tumors, while HRS-4508 is a tyrosine kinase inhibitor that inhibits the proliferation of tumor cells.The pharmaceutical company has invested 160.9 million yuan into the research and development of HRS-6209 and 96.7 million yuan in HRS-4508's research.Hengrui's Shanghai and Hong Kong shares both slipped 1% during the morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","01276","LU1064130708.USD","LU1328615791.USD","LU1023057109.AUD","BK0012","LU2328871848.SGD","LU0405327494.USD","LU2148510915.USD","BK1191","LU1997245094.SGD","LU1997245177.USD","LU2097828631.EUR","600276","LU1255011170.USD","LU2097828474.EUR","LU2580892862.HKD","BK0183","LU2488822045.USD","LU0359201612.USD","LU2495084118.USD","LU1655091616.SGD","LU2097828557.USD","LU1146622755.USD","LU2580892789.USD","LU1781817850.SGD","LU1997244956.HKD","LU1820825898.SGD","LU1064131003.USD","LU1969619763.USD","LU2097828805.USD","LU0359201885.HKD","BK0239","LU0359202008.SGD","BK0060","BK0188","LU1580142542.USD","BK0028","LU2097828714.EUR","LU2543165471.USD","LU2289578879.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}